Discussion on the issue of sample size determination for a targeted to an untargeted and to a mixed effect model-based clinical trial design

References

• A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, A. Rosenwald, J.C. Boldrick, H. Sabet, T. Tran, X. Yu, J.I. Powell, L. Yang, G.E. Marti, T. Moore, J. Hudson, L. Lu, D.B. Lewis, R. Tibshirani, G. Sherlock, W.C. Chan, T.C. Greiner, D.D. Weisenburger, J.O. Armitage, R. Warnke, R. Levy, W. Wilson, M.R. Grever, J.C. Byrd, D. Botstein, P.O. Brown, and L.M. Staudt, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403 (2000), pp. 503–511. doi: 10.1038/35000501
   PubMed Web of Science ®Google Scholar
• R.A. Betensky, D.N. Louis, and J.G. Cairncross, Influence of unrecognized molecular heterogeneity on randomized trials, J. Clin. Oncol. 20 (2002), pp. 2495–2499. doi: 10.1200/JCO.2002.06.140
   PubMed Web of Science ®Google Scholar
• E. Brittain and J. Wittes, The run-in period in clinical trials. The effect of misclassification on efficiency, Control. Clin. Trials 11 (1990), pp. 327–338. doi: 10.1016/0197-2456(90)90174-Z
   PubMedGoogle Scholar
• Y. Caraco, Genes and the response to drugs, N. Engl. J. Med. 351 (2004), pp. 2867–2869. doi: 10.1056/NEJMe048278
   PubMed Web of Science ®Google Scholar
• S.M. Crusz, Y.Z. Tang, S.J. Sarker, W. Prevoo, I. Kiyani, L. Beltran, J. Peters, A. Sahdev, A. Bex, T. Powles, and M. Gerlinger, Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma, BMC. Med. 14 (2016), pp. 185. doi: 10.1186/s12916-016-0729-9.
   PubMed Web of Science ®Google Scholar
• M. Eichebaum, N. Spannbrucker, B. Steincke, and H.J. Dengler, Defective N-oxidation of sparteine in man: A new pharmacogenetic defect, Eur. J. Clin. Pharmacol. 16 (1979), pp. 183–187. doi: 10.1007/BF00562059
   PubMed Web of Science ®Google Scholar
• R.C. Elston, R.M. Idury, L.R. Cardon, and J.B. Lichter, The study of candidate genes in drugs trials: Sample size considerations, Stat. Med. 18 (1999), pp. 741–751. doi: 10.1002/(SICI)1097-0258(19990330)18:6<741::AID-SIM64>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• B.A. Fijal, J.M. Hall, and J.S. Witte, Clinical trials in the genomic era: Effects of protective genotypes on sample size and duration of trial, Control. Clin. Trials. 21 (2000), pp. 7–20. doi: 10.1016/S0197-2456(99)00039-2
   PubMedGoogle Scholar
• E. Fox, G.A. Curt, and F.M. Balis, Clinical trial design for target-based therapy, Oncologist 7 (2002), pp. 401–409. doi: 10.1634/theoncologist.7-5-401
   PubMed Web of Science ®Google Scholar
• B. Freidlin, L.M. McShane, and E.L. Korn, Randomized clinical trials with biomarkers: Design issues, J. Natl. Cancer Inst. 102 (2010), pp. 152–160. doi: 10.1093/jnci/djp477
   PubMed Web of Science ®Google Scholar
• IRESSA gefitinib tablets 250 mg for Oncology Use Only. Available at http://www.fda.gov/cder/foi/label/2003/21399_iressa_lbl.pdf.
   Google Scholar
• A. Kallioniemi, O.P. Kallioniemi, D. Sudar, D. Rutovitz, J.W. Gray, F. Waldman, and D. Pinkel, Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors, Science 258 (1992), pp. 818–821. doi: 10.1126/science.1359641
   PubMed Web of Science ®Google Scholar
• F.S. Ko, Approaches to allocate sample size rationally into individual regions for a multi-regional trial under heterogeneous effect size, Comm. Statist. Theory Methods 41 (2012), pp. 3648–3665. doi: 10.1080/03610926.2011.564741
   Web of Science ®Google Scholar
• F.S. Ko, Comparisons of allocating sample size rationally into individual regions under heterogeneous effect size in a multi-regional trial by a fixed effect model and a random effect Model, Comm. Statist. Theory Methods 45 (2016), pp. 7060–7074. doi: 10.1080/03610926.2014.974823
   Web of Science ®Google Scholar
• A. Mahgoab, J.R. Idle, L.G. Drig, R. Lancaster, and R.L. Smith, Polymorphic hydroxylation of debrisoquine in man, Lancet 2 (1977), pp. 584–586. doi: 10.1016/S0140-6736(77)91430-1
   PubMed Web of Science ®Google Scholar
• A. Maitournam and R. Simon, On the efficiency of targeted clinical trials, Stat. Med. 24 (2005), pp. 329–339. doi: 10.1002/sim.1975
   PubMed Web of Science ®Google Scholar
• C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, J. Johnsen, L.A. Akslen, Ø. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A-L. Børresen-Dale, P.O. Brown, and D. Botstein, Molecular portraits of human breast tumours, Nature 406 (2000), pp. 747–752. doi: 10.1038/35021093
   PubMed Web of Science ®Google Scholar
• D.J. Sargent, B.A. Conley, C. Allegra, and L. Collette, Clinical trial designs for predictive marker validation in cancer treatment trials, J. Clin. Oncol. 23 (2005), pp. 2020–2027. doi: 10.1200/JCO.2005.01.112
   PubMed Web of Science ®Google Scholar
• D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med. 344 (2001), pp. 783–792. doi: 10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• S.J. Wang, R.T. O'Neill, and H.M. Hung, Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset, Pharm. Stat. 6 (2007), pp. 227–244. doi: 10.1002/pst.300
   PubMed Web of Science ®Google Scholar
• Y.J. Wu, C.T. Chen, H.H. Tsou, and C.F. Hsiao, Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials, Drug Des. 4 (2015), pp. 120. doi: 10.4172/2169-0138.1000120.
   Google Scholar